NovoCure Limited

Equities

NVCR

JE00BYSS4X48

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:00:00 2026-02-10 pm EST			5-day change	1st Jan Change
10.47 ^USD	+4.39%		-11.57%	-19.03%

Jan. 14	NovoCure Limited Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-14-2026 09:45 AM
Jan. 12	NovoCure Reports Rise in Q4 Preliminary Revenue	MT

NovoCure Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025

Published on 10/30/2025 at 11:46 am EDT - Modified on 10/30/2025 at 07:00 am EDT

S&P Capital IQ

NOVOCURE LIMITED

+4.39%

NovoCure Limited reported earnings results for the third quarter and nine months ended September 30, 2025. For the third quarter, the company reported sales was USD 167.2 million compared to USD 155.1 million a year ago. Net loss was USD 37.27 million compared to USD 30.57 million a year ago. Basic loss per share from continuing operations was USD 0.33 compared to USD 0.28 a year ago.
For the nine months, sales was USD 481 million compared to USD 443.95 million a year ago. Net loss was USD 111.73 million compared to USD 102.71 million a year ago. Basic loss per share from continuing operations was USD 1 compared to USD 0.95 a year ago.

Latest news about NovoCure Limited

Jan. 14	NovoCure Limited Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-14-2026 09:45 AM
Jan. 12	NovoCure Reports Rise in Q4 Preliminary Revenue	MT
Dec. 01	Novocure Limited Announces CEO Changes	CI
Dec. 01	Novocure appoints company president Frank Leonard as chief executive officer	RE
Dec. 01	NovoCure Names Frank Leonard as Chief Executive	MT
25-10-30	NovoCure Limited, Q3 2025 Earnings Call, Oct 30, 2025
25-10-30	NovoCure Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-10-30	NovoCure Q3 Net Loss Widens, Revenue Rises	MT
25-10-30	Novocure Q3 revenue beats estimates	RE
25-10-30	Earnings Flash (NVCR) Novocure Limited Reports Q3 Revenue $167.20M, vs. FactSet Est of $158.9M	MT
25-10-01	Novocure to report third quarter 2025 financial results	RE
25-09-29	Novocure to present final results from pivotal phase 3 Metis trial of its Tumor Treating Fields therapy for brain metastases from non-small cell lung cancer at 2025 Astro Annual Meeting	RE
25-09-29	Novocure to Present Final Results from the Pivotal Phase 3 METIS Trial of Its Tumor Treating Fields Therapy for Brain Metastases from Non-Small Cell Lung Cancer At 2025 ASTRO Annual Meeting	CI
25-09-15	Novocure's Optune Lua® Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non-Small Cell Lung Cancer	CI
25-09-15	NovoCure's Optune Lua Receives Approval in Japan to Treat Certain Non-Small Cell Lung Cancer Patients	MT
25-09-10	NovoCure Limited Presents at Morgan Stanley 23rd Annual Global Healthcare Conference, Sep-10-2025 03:20 PM
25-09-08	Novocure Insider Bought Shares Worth $996,859, According to a Recent SEC Filing	MT
25-08-25	Novocure Announces Coverage of Tumor Treating Fields Therapy for Patients with Newly Diagnosed Glioblastoma in Spain	CI
25-08-25	NovoCure's TTFields Now Covered by Spanish National Health System	MT
25-08-20	NovoCure Limited Submits Premarket Approval Application to FDA for Tumor Treating Fields Therapy in Locally Advanced Pancreatic Cancer	CI
25-08-20	NovoCure Submits FDA Premarket Approval Application for Tumor Treating Files Therapy for Pancreatic Cancer	MT
25-07-25	NovoCure Shares Fall After Wells Fargo Downgrade	MT
25-07-25	Wells Fargo Downgrades NovoCure to Equalweight From Overweight, Adjusts Price Target to $14.50 From $40	MT
25-07-24	NovoCure Limited, Q2 2025 Earnings Call, Jul 24, 2025
25-07-24	Wedbush Cuts Price Target on NovoCure to $18 From $27, Maintains Neutral Rating	MT

Chart NovoCure Limited

Duration

Period

NVCR: Dynamic Chart

Company Profile

NovoCure Limited is a global oncology company. The Company is engaged in the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua for the treatment of solid tumor cancers. Its commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and pleural mesothelioma. It is conducting pivotal studies evaluating the use of TTFields in the treatment of ovarian cancer, brain metastases from non-small cell lung cancer (NSCLC) (brain metastases) and pancreatic cancer. Its key priorities are to drive commercial adoption of Optune, its commercial TTFields device. It also has a license to market Optune in China, Hong Kong, Macau and Taiwan. It has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.

Employees

1,488

Sector

Medical Equipment, Supplies & Distribution

Calendar

Feb. 25 - Q4 2025 Earnings Release

More about the company